Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentatio...
May 20 2021 - 7:30AM
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, today announced that the
latest data from HS-110, the Company’s lead product, has been
accepted for poster presentation at the 2021 American Society of
Clinical Oncology (ASCO) Annual Meeting, to be held virtually from
June 4-8, 2021. The ASCO Annual Meeting is the largest
international conference to showcase the latest advancements in
oncology.
Abstract
Title: Interim results of viagenpumatucel-L (HS-110) plus
nivolumab in previously treated patients (pts) with advanced
non-small cell lung cancer (NSCLC) in two treatment settings
Session
Title: Poster Session: Lung Cancer—Non-Small Cell
Metastatic
Abstract
Number: 9100
Lead Author
and Presenter: Roger B. Cohen, MD, Perelman School of
Medicine at the University of Pennsylvania
According to ASCO, more than 5,400 abstracts
were reviewed for the 2021 ASCO Annual Meeting. Additional
information about the conference may be accessed at
https://conferences.asco.org/am/attend.
About HS-110HS-110 is a
first-in-class, off-the-shelf, allogeneic cell therapy designed to
utilize gp96 for immune activation against multiple tumor testis
antigens. Phase 2 trial of HS-110 in combination with Bristol-Myers
Squibb's (BMS) OPDIVO® (nivolumab) has completed enrollment in
patients with incurable or metastatic NSCLC. OPDIVO® is a
programmed death-1 immune checkpoint inhibitor (PD-1 inhibitor).
HS-110 has broad potential for providing multiple treatment options
to NSCLC patients in combination with a PD-1 inhibitor. Positive
interim survival data has been demonstrated in two distinct
treatment settings in previously treated NSCLC patients who have
not been treated with PD-1 inhibitor or programmed death-ligand 1
inhibitor (PD-L1 inhibitor) as well as patients who have progressed
during or after previous treatment with a PD-1 or PD-L1 [PD-(L)1]
inhibitor. Combination of HS-110 and PD-(L)1 therapies may confer
additional survival benefit.
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, and a COVID-19
vaccine program in preclinical development. In addition, Heat
Biologics is also developing a pipeline of proprietary
immunomodulatory antibodies and cell-based therapies, including
PTX-35 and HS-130 in Phase 1 clinical trials.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements such as the broad potential of HS-110 for providing
multiple treatment options to NSCLC patients in combination with a
PD-1 inhibitor. These statements are subject to a number of
risks and uncertainties, many of which are difficult to predict,
the ability of Heat's therapies to perform as designed, to
demonstrate safety and efficacy, as well as results that are
consistent with prior results, Heat's vaccine platform to provide
protection against COVID-19, the ability to enroll patients and
complete the clinical trials on time and achieve desired results
and benefits, especially in light of COVID-19, Heat's ability to
obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to Heat's ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, Heat's
ability to maintain its license agreements, the continued
maintenance and growth of its patent estate, its ability to
establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, its ability to continue to maintain its
listing on the Nasdaq Capital Market and its ability to retain its
key scientists or management personnel, and the other factors
described in Heat's most recent annual report on Form 10-K filed
with the SEC, and other subsequent filings with the SEC. The
information in this release is provided only as of the date of this
release, and Heat undertakes no obligation to update any
forward-looking statements contained in this release based on new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024